Commack, New York
United States
24
2024-03-07
The entities that hold a legal rights for patent applications filed by inventor Mo Yun:
Yun Mo from Commack, US has applied for patents for these inventions. The list has both pending applications and granted patents:
Low-Dose Stable Formulations of Linaclotide
#2 | 2023-11-02Stable Formulations of Linaclotide
#3 | 2022-07-28Stable Formulations of Linaclotide
#4 | 2022-02-03Low-Dose Stable Formulations of Linaclotide
#5 | 2020-02-06Low-Dose Stable Formulations of Linaclotide
#6 | 2020-01-30Stable formulations of linaclotide
#7 | 2019-07-11Stable formulations of linaclotide
#8 | 2019-01-31Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
#9 | 2018-01-18Low-Dose Stable Formulations of Linaclotide
#10 | 2017-06-08Low-Dose Stable Formulations of Linaclotide
#11 | 2016-10-27Low-Dose Stable Formulations of Linaclotide
#12 | 2016-10-27Delayed Release Compositions of Linaclotide
#13 | 2015-05-14Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
#14 | 2015-01-29Orally Disintegrating Compositions of Linaclotide
#15 | 2014-12-25Stable Formulations of Linaclotide
#16 | 2014-09-25Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
#17 | 2014-01-23MILNACIPRAN FORMULATIONS
#18 | 2014-01-02TREATMENTS OF GASTROINTESTINAL DISORDERS
#19 | 2013-10-17Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
#20 | 2013-01-10Orally Disintegrating Compositions of Linaclotide
#21 | 2012-08-23Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
#22 | 2011-03-10Formulations comprising linaclotide
#23 | 2010-11-11MILNACIPRAN FORMULATIONS
#24 | 2010-02-25Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
29715 ⎘